In the same period a year ago the company posted earnings of 74 cents a share on sales of $7.6 billion.
The stock has risen 1.7% since the company last reported earnings on Oct. 17. Quarterly estimates have fallen less than 1 cent a share in the past month.
Abbott Laboratories is currently trading at a price-to-forward-earnings ratio of 22 based on the 12-month estimates of 23 analysts surveyed by FactSet.
Johnson & Johnson and Abbott Laboratories are holdings in Jim Cramer's Action Alerts portfolio. Want to be alerted before Jim Cramer buys or sells JNJ or ABT? Learn more now.